Kuwana M, Kaburaki J, Ikeda Y
Department of Internal Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan.
J Clin Invest. 1998 Oct 1;102(7):1393-402. doi: 10.1172/JCI4238.
T cell proliferative responses to platelet membrane GPIIb-IIIa were examined in 14 patients with chronic immune thrombocytopenic purpura (ITP), 7 systemic lupus erythematosus (SLE) patients with or without thrombocytopenia, and 10 healthy donors. Although peripheral blood T cells from all subjects failed to respond to the protein complex in its native state, reduced GPIIb-IIIa stimulated T cells from three ITP patients and one SLE patient with thrombocytopenia, and tryptic peptides of GPIIb-IIIa stimulated T cells from nearly all subjects. The specificity of the responses for GPIIb-IIIa was confirmed by activation of GPIIb-IIIa-primed T cells by a recombinant GPIIbalpha fragment in secondary cultures. Characterization of T cell response induced by modified GPIIb-IIIa showed that the response was restricted by HLA-DR, the responding T cells had a CD4(+) phenotype, and the proliferation was accelerated only in ITP patients, suggesting in vivo activation of these T cells. In vitro IgG anti-GPIIb-IIIa synthesis in PBMC cultures was induced by modified GPIIb-IIIa specifically in ITP patients with platelet-associated anti-GPIIb-IIIa antibody. Anti-GPIIb-IIIa antibody produced in supernatants was absorbed by incubation with normal platelets. In summary, CD4(+) and HLA-DR-restricted T cells to GPIIb-IIIa are involved in production of anti-platelet autoantibody in ITP patients and are related to the pathogenic process in chronic ITP.
在14例慢性免疫性血小板减少性紫癜(ITP)患者、7例有或无血小板减少的系统性红斑狼疮(SLE)患者以及10名健康供者中检测了T细胞对血小板膜糖蛋白IIb-IIIa(GPIIb-IIIa)的增殖反应。尽管所有受试者的外周血T细胞对天然状态的蛋白复合物均无反应,但还原型GPIIb-IIIa刺激了3例ITP患者和1例有血小板减少的SLE患者的T细胞,且GPIIb-IIIa的胰蛋白酶消化肽刺激了几乎所有受试者的T细胞。在二次培养中,重组GPIIbα片段激活GPIIb-IIIa预致敏的T细胞,证实了对GPIIb-IIIa反应的特异性。对修饰后的GPIIb-IIIa诱导的T细胞反应的特征分析表明,该反应受HLA-DR限制,反应性T细胞具有CD4(+)表型,且仅在ITP患者中增殖加速,提示这些T细胞在体内被激活。在体外,修饰后的GPIIb-IIIa特异性地在有血小板相关抗GPIIb-IIIa抗体的ITP患者的外周血单核细胞(PBMC)培养物中诱导IgG抗GPIIb-IIIa合成。上清液中产生的抗GPIIb-IIIa抗体与正常血小板孵育后被吸收。总之,针对GPIIb-IIIa的CD4(+)和HLA-DR限制的T细胞参与ITP患者抗血小板自身抗体的产生,并与慢性ITP的致病过程相关。